Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice

Dagmar Wertaschnigg; Maya Reddy; Ben W.J. Mol; Fabricio Da Silva Costa; Daniel L. Rolnik

doi:10.1155/2019/2675101

Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice

Dagmar Wertaschnigg^*, Maya Reddy, Ben W.J. Mol, Fabricio Da Silva Costa, Daniel L. Rolnik

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

2 Downloads (Pure)

Abstract

In this review, we discuss the recent literature regarding the prevention of preeclampsia and aim to answer common questions that arise in the routine antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk patients has been shown to reduce the risk of preeclampsia (PE). A daily dose between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks of gestation and can be continued until delivery. Calcium supplementation seems to be advantageous but currently it is only considered for patients with poor dietary intake and high risk for PE. Recent data about heparin are still conflicting, and therefore, heparin can currently not be recommended in the prevention of PE.

Original language	English
Article number	2675101
Journal	Journal of Pregnancy
Volume	2019
DOIs	https://doi.org/10.1155/2019/2675101
Publication status	Published - 1 Aug 2019

Bibliographical note

Acknowledgments Dagmar Wertaschnigg is supported by a grant from the Paracelsus Medical University Salzburg, Austria [PMU Research Fund–PMU FFF Number: L-18/02/006-WET], and by Drs Haackert Foundation, Germany.

Access to Document

10.1155/2019/2675101

Wertaschnigg_etal_JP_Evidence-based_Prevention_of_VOR
Copyright Copyright © 2019 Dagmar Wertaschnigg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 1.53 MBLicence: CC BY

Cite this

@article{6e00488a54c749beb17ae5b219e5ecab,

title = "Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice",

abstract = "In this review, we discuss the recent literature regarding the prevention of preeclampsia and aim to answer common questions that arise in the routine antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk patients has been shown to reduce the risk of preeclampsia (PE). A daily dose between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks of gestation and can be continued until delivery. Calcium supplementation seems to be advantageous but currently it is only considered for patients with poor dietary intake and high risk for PE. Recent data about heparin are still conflicting, and therefore, heparin can currently not be recommended in the prevention of PE.",

author = "Dagmar Wertaschnigg and Maya Reddy and Mol, {Ben W.J.} and {Da Silva Costa}, Fabricio and Rolnik, {Daniel L.}",

note = "Acknowledgments Dagmar Wertaschnigg is supported by a grant from the Paracelsus Medical University Salzburg, Austria [PMU Research Fund–PMU FFF Number: L-18/02/006-WET], and by Drs Haackert Foundation, Germany.",

year = "2019",

month = aug,

day = "1",

doi = "10.1155/2019/2675101",

language = "English",

volume = "2019",

journal = "Journal of Pregnancy",

issn = "2090-2727",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Evidence-Based Prevention of Preeclampsia

T2 - Commonly Asked Questions in Clinical Practice

AU - Wertaschnigg, Dagmar

AU - Reddy, Maya

AU - Mol, Ben W.J.

AU - Da Silva Costa, Fabricio

AU - Rolnik, Daniel L.

N1 - Acknowledgments Dagmar Wertaschnigg is supported by a grant from the Paracelsus Medical University Salzburg, Austria [PMU Research Fund–PMU FFF Number: L-18/02/006-WET], and by Drs Haackert Foundation, Germany.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - In this review, we discuss the recent literature regarding the prevention of preeclampsia and aim to answer common questions that arise in the routine antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk patients has been shown to reduce the risk of preeclampsia (PE). A daily dose between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks of gestation and can be continued until delivery. Calcium supplementation seems to be advantageous but currently it is only considered for patients with poor dietary intake and high risk for PE. Recent data about heparin are still conflicting, and therefore, heparin can currently not be recommended in the prevention of PE.

AB - In this review, we discuss the recent literature regarding the prevention of preeclampsia and aim to answer common questions that arise in the routine antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk patients has been shown to reduce the risk of preeclampsia (PE). A daily dose between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks of gestation and can be continued until delivery. Calcium supplementation seems to be advantageous but currently it is only considered for patients with poor dietary intake and high risk for PE. Recent data about heparin are still conflicting, and therefore, heparin can currently not be recommended in the prevention of PE.

UR - http://www.scopus.com/inward/record.url?scp=85071098688&partnerID=8YFLogxK

U2 - 10.1155/2019/2675101

DO - 10.1155/2019/2675101

M3 - Review article

C2 - 31467716

AN - SCOPUS:85071098688

SN - 2090-2727

VL - 2019

JO - Journal of Pregnancy

JF - Journal of Pregnancy

M1 - 2675101

ER -

Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this